Selinexor
CAS 1393477-72-9 1 FDA-DMF supplierSmall Molecule
Overview
Selinexor is a selective inhibitor of nuclear export (SINE) compound used in cancer treatment. It works by blocking the export of tumor suppressor proteins from the nucleus, leading to their accumulation and activation in the nucleus, which induces apoptosis in cancer cells.
Patent & exclusivity (US)
Per the FDA Orange Book (6 approved US products), the latest listed US patent on Selinexor expires 13 Aug 2035 and exclusivity 18 Dec 2027. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Oncology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.